BioCentury | Oct 17, 2011
Finance

Banker tracks

...head a new office in McLean, Va. Young was SVP and managing director of the Mid-Atlantic technology...
BioCentury | Feb 23, 2009
Emerging Company Profile

CT Atlantic: Reverse translation

Reverse translational medicine, the practice of developing therapeutics by studying patients who have a less severe disease state than others, has governed the development of vaccines against infectious disease for two centuries. CT Atlantic AG...
BioCentury | Apr 12, 2004
Strategy

Indevus' pipeline

...prevention Moving into Ph II/III in 2004 Procept IP 751 Pain and inflammation Ph II Atlantic Technology...
BioCentury | Dec 23, 2002
Company News

Atlantic Technology, Manhattan deal

...small molecule is in preclinical development. ATLC had $375,845 in cash as of Sept. 30. Atlantic Technology Ventures Inc....
BioCentury | Dec 17, 2002
Company News

ATLC to merge with Manhattan Pharma

Atlantic Technology Ventures (ATLC) will merge with Manhattan Pharmaceuticals (New York, N.Y.), which develops therapeutics for obesity. Upon completion of the merger, ATLC will own about 20% and Manhattan will own about 80% of the...
BioCentury | Dec 9, 2002
Finance

Ebb & Flow

...Stock Exchange, while on NASDAQ, IDBE was up $0.36 to $6.29. Indevus (IDEV) and licensor Atlantic Technology...
BioCentury | Dec 9, 2002
Clinical News

IP 751: Phase II

...the other regimen during the second week. IDEV has a license to IP 751 from Atlantic Technology Ventures Inc....
BioCentury | Dec 3, 2002
Clinical News

Indevus Phase II pain data

...the compound did not have psychoactive properties. IDEV has a license to IP 751 from Atlantic Technology...
BioCentury | Jul 15, 2002
Company News

Atlantic Technology, University of Innsbruck deal

...down regulation of proinflammatory cytokines such as tumor necrosis factor , nitric oxide and prostaglandins. Atlantic Technology Ventures Inc....
BioCentury | Jul 8, 2002
Company News

Atlantic Technology, Indevus deal

...pain. ATLC will receive an upfront licensing fee and is eligible for milestones and royalties. Atlantic Technology Ventures Inc....
Items per page:
1 - 10 of 21
BioCentury | Oct 17, 2011
Finance

Banker tracks

...head a new office in McLean, Va. Young was SVP and managing director of the Mid-Atlantic technology...
BioCentury | Feb 23, 2009
Emerging Company Profile

CT Atlantic: Reverse translation

Reverse translational medicine, the practice of developing therapeutics by studying patients who have a less severe disease state than others, has governed the development of vaccines against infectious disease for two centuries. CT Atlantic AG...
BioCentury | Apr 12, 2004
Strategy

Indevus' pipeline

...prevention Moving into Ph II/III in 2004 Procept IP 751 Pain and inflammation Ph II Atlantic Technology...
BioCentury | Dec 23, 2002
Company News

Atlantic Technology, Manhattan deal

...small molecule is in preclinical development. ATLC had $375,845 in cash as of Sept. 30. Atlantic Technology Ventures Inc....
BioCentury | Dec 17, 2002
Company News

ATLC to merge with Manhattan Pharma

Atlantic Technology Ventures (ATLC) will merge with Manhattan Pharmaceuticals (New York, N.Y.), which develops therapeutics for obesity. Upon completion of the merger, ATLC will own about 20% and Manhattan will own about 80% of the...
BioCentury | Dec 9, 2002
Finance

Ebb & Flow

...Stock Exchange, while on NASDAQ, IDBE was up $0.36 to $6.29. Indevus (IDEV) and licensor Atlantic Technology...
BioCentury | Dec 9, 2002
Clinical News

IP 751: Phase II

...the other regimen during the second week. IDEV has a license to IP 751 from Atlantic Technology Ventures Inc....
BioCentury | Dec 3, 2002
Clinical News

Indevus Phase II pain data

...the compound did not have psychoactive properties. IDEV has a license to IP 751 from Atlantic Technology...
BioCentury | Jul 15, 2002
Company News

Atlantic Technology, University of Innsbruck deal

...down regulation of proinflammatory cytokines such as tumor necrosis factor , nitric oxide and prostaglandins. Atlantic Technology Ventures Inc....
BioCentury | Jul 8, 2002
Company News

Atlantic Technology, Indevus deal

...pain. ATLC will receive an upfront licensing fee and is eligible for milestones and royalties. Atlantic Technology Ventures Inc....
Items per page:
1 - 10 of 21